Genentech, a member of the Roche Group announced today that it will present more than 40 abstracts across nine blood disorders at the 66th American Society of Hematology Annual Meeting and ...

You may also report side effects to Genentech at (888) 835-2555. PiaSky® is a prescription medicine used to treat a disease called paroxysmal nocturnal hemoglobinuria (PNH) in adults and children ...

and PiaSky (Genentech/Roche), offering new mechanisms for treatment. In just over a year, Fabhalta has gained substantial traction, with physician consideration for first-line use doubling year ...

Roche Holding AG’s Genentech Inc. unit received U.S. FDA approval on June 20 of Piasky (crovalimab) to treat adults and children 13 and older with paroxysmal nocturnal hemoglobinuria and a body weight ...

PiaSky is the first monthly subcutaneous (SC ... our efforts to improve access to healthcare together with local partners in every country we work. Genentech, in the United States, is a wholly owned ...

Treatment with crovalimab met both coprimary endpoints demonstrating noninferiority to eculizumab for transfusion avoidance and hemolysis control. The Food and Drug Administration (FDA) has ...

Five-year data from the Phase III POLARIX study (abstract #469) reinforce the potential of Polivy in combination with Rituxan ® (rituximab), cyclophosphamide, doxorubicin and prednisone (R-CHP ...